AI in Antibody Biologics Discovery – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The application of AI and ML technologies for biologics screening is a high-impact innovation with strong commercial activity, including acquisitions and partnerships among key players. Patenting activity in this area has been consistently growing since 2018, with a significant increase in 2023. The rapid growth is attributed to the rise in AI technology, with a technology cycle time of 1.1 years. China and the US are the leading geographies in this field, with over 40% of all patents filed by universities. Among the 40+ companies identified in this space, China-based tech companies Baidu and Ping An are in the top-10, along with Merck & Co, BioNTech, Alphabet, NEC, Accenture, IBM, Microsoft, Evaxion, iBio, and Codexis.

The application of new AI & ML technologies for biologics screening in drug discovery has been identified as a high-impact innovation with strong commercial activity. Patenting activity has been steadily increasing since 2018, with a notable doubling in 2023, driven by the rapid growth of AI technology. The technology cycle time for AI-based biologics screening is 1.1 years, indicating quick development cycles. China and the US are leading geographies in this field, with universities filing over 40% of all patents. Competitive intelligence reveals top players such as Baidu, Ping An, Merck & Co, and BioNTech, with tech companies like Alphabet, NEC, and IBM leading the way. Evaxion, iBio, and Codexis are prominent in the healthtech sector.

How is our ‘State of Innovation intelligence 2024’ report unique from other reports in the market?

360° Market View: It consolidates patents, drugs, clinical trials, and deals data into one comprehensive resource, unlike many reports that focus on a single data type.
Targeted AI Insights: Specifically tailored to the intersection of AI and biological drug discovery, it delivers focused insights on how AI is transforming the drug discovery process.
Competitive Landscape Analysis: Offers deep competitive intelligence by tracking both established players and emerging startups, including strategic partnerships and investment trends.
Actionable Intelligence: Equips stakeholders with actionable insights to refine R&D strategies, identify licensing opportunities, and navigate regulatory challenges.
Advanced Analytics: Utilizes state-of-the-art data analytics and visualization techniques to turn complex data into clear, strategic guidance.

We recommend this valuable source of information to anyone involved in –

​​​​Drug Development and ​​​​Pharma/Biotech Companies – Value chain
Pharmaceutical Industry Suppliers and Distributors
Pharma/Drug Manufacturing Companies – Leaders and Startups
Business Development and Market Intelligence
Investment Analysts and Portfolio Managers
Professional Services – Investment Banks, PE/VC Firms
M&A/Investment, Management Consultants, and Consulting Firms

Scope

Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.

Key player: This represents a sample list of key players in each use case highlighted in the report.

Startups: This represents a sample list of emerging starups in each use case highlighted in the report.

University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

AI for biologics screening is a high-impact innovation with strong commercial activity, including asset-driven acquisitions and co-development partnerships.

Patenting activity has been steadily growing since 2018, doubling in 2023, driven by the rapid growth of AI technology.

Technology cycle time for AI-based biologics screening is 1.1 years, indicating quick development cycles.

China and the US are leading geographies in this field, with universities filing over 40% of all patents.

Top players include Baidu, Ping An, Merck & Co, and BioNTech, with tech companies like Alphabet, NEC, and IBM leading the way in competitive intelligence.

Reasons to Buy

1. Comprehensive Market Overview – Gain a holistic understanding of the growing role of AI and ML technologies in biologics screening, including insights into patents, clinical trials, and strategic industry deals.

2. Track Cutting-Edge Innovations – Stay at the forefront by exploring how AI is revolutionizing biologics screening, with an emphasis on breakthrough research, emerging technologies, and industry developments.

3. Competitive Landscape Analysis – Identify leading players in AI-driven biologics screening, such as Baidu, Merck, BioNTech, and more, to help position your company for success in this rapidly advancing sector.

4. Optimize R&D Strategy – Leverage insights to streamline your research and development processes, refine biologics screening pipelines, and accelerate time-to-market for innovative treatments.

5. Navigate IP and Regulatory Challenges – Understand patent trends and potential regulatory hurdles to mitigate risks and identify valuable licensing and intellectual property opportunities.

6. Investment & Partnership Insights – Discover key M&A activity, partnership trends, and investment opportunities in the AI-driven biologics space to guide future growth and strategic collaborations.

Baidu Inc,Alphabet,Ping An,Ibio,BOE Technology,Just-Evotec,Deep Genomics,Recursion Pharma,Labgenius
Equillium,IoGenetics,Microsoft,Gristone Bio,Oncocross,Flagship Poineering,X dev,3billion,CSTS Healthcare,IBM,NCE Corporation,DNAStar,Evaxion,Insitro

Table of Contents

Table of Contents

1. Innovation Insights

1.1 Innovation radar

1.2 Innovation s-curve

1.3 Innovation deep dive

1.4 Innovation deep dive – trending indications

1.5 Top companies Based on portfolio strength and temporal indicators

2. Competitive Insights

2.1 Key innovation leaders – big pharma

2.2.Key innovators – startups and small biotech

2.3 Key innovations – Universities and research institutions

2.4 Most cited patents

2.5 Insights from AI hub

3.Market Insights

3.1 Drugs

3.1.1 Key Players

3.1.2 Route of administration & drug type

3.1.3 Top therapy area & indication

3.2 Clinical Trials

3.2.1 Key Sponsors

3.2.2 Key development stages

3.3 Deals

3.3.1. Key Acquirers

3.3.2 Deal type distribution

3.3.3 Geographical distribution

AI in Antibody Biologics Discovery – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals standard reports
Currency USD
$2,499

Can be used by individual purchaser only

$7,497

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

AI in Antibody Biologics Discovery – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Pharmaceuticals
New
Gonorrhea: Market View, Current and Future Competitive Landscape
$3,495 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at AI in Antibody Biologics Discovery – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals in real time.

  • Access a live AI in Antibody Biologics Discovery – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.